Psychopharmacology of autism spectrum disorders

Pediatric Clinics of North America

Volumn 59, Issue 1, 2012, Pages 175-187

  Kaplan, Gabriel ^a,b   McCracken, James T ^c  

^a Hoboken University Medical Center   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotics; Autism; Autism spectrum disorders; Hyperactivity; Irritability; Psychopharmacology; Repetitive behaviors; Stimulants

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; CLONIDINE; ESCITALOPRAM; FLUOXETINE; GUANFACINE; HALOPERIDOL; MELATONIN; METHYLPHENIDATE; NALTREXONE; NEUROLEPTIC AGENT; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM;

ABERRANT BEHAVIOR CHECKLIST; AGITATION; ALLERGIC REACTION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; CHILDREN PSYCHIATRIC RATING SCALE; CHILDREN YALE BROWN OBSESSIVE COMPULSIVE SCALE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; COMPULSION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INFANTILE AUTISM; INSOMNIA; IRRITABILITY; LETHARGY; MOOD CHANGE; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL CARE; PSYCHOSOMATIC DISORDER; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SPEECH THERAPY; STEREOTYPY; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; HUMANS; INFANT; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPHARMACOLOGY;

EID: 84856291271     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2011.10.005     Document Type: Review

References (56)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, text revision, APA, Washington, DC. 4th edition.
2. Levy S.E., Mandell D.S., Schultz R.T. Autism. Lancet 2009, 374:1627-1638.
3. Rutter M. Aselective scientific history of Autism. Textbook of ASD 2011, 5-21. APPI, Washington, DC. E. Hollander, A. Kolevzon, J. Coyle (Eds.).
4. Myers S.M., Johnson C.P. Management of children with ASD. Pediatrics 2007, 120(5):1162-1182.
5. Krishnaswami S., McPheeters M.L., Veenstra-Vanderweele J. Asystematic review of secretin for children with autism spectrum disorders. Pediatrics 2011, 127(5):e1322-e1325.
6. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ No ADM 76-338) 1976, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville (MD), p. 218-22.
7. Aman M.G., Singh N.N., Stewart A.W., et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985, 89:485-491.
8. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985, 21(4):714-1124.
9. Scahill L., McDougle C.J., Williams S.K., et al. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. JAm Acad Child Adolesc Psychiatry 2006, 45(9):1114-1123.
10. Kanne S.M., Mazurek M.O. Aggression in children and adolescents with ASD: prevalence and risk factors. JAutism Dev Disord 2011, 41(7):926-937.
11. Campbell M., Anderson L.T., Meier M., et al. Acomparison of haloperidol and behavior therapy and their interaction in autistic children. JAm Acad Child Psychiatry 1978, 17:640-655.
12. Mandell D., Morales K., Marcus S.C., et al. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 2008, 121:e441-e448.
13. Anderson L.T., Campbell M., Grega D.M., et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984, 141(10):1195-1202.
14. Campbell M., Armenteros J., Malone R.P., et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. JAm Acad Child Adolesc Psychiatry 1997, 36(6):835-843.
15. Posey D.J., Stigler K.A., Erickson C.A., et al. Antipsychotics in the treatment of autism. JClin Invest 2008, 118:6-14.
16. RUPP Risperidone in children with autism and serious behavioral problems. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. NEngl J Med 2002, 347:314-321.
17. RUPP Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Am J Psychiatry 2005, 162:1361-1369.
18. Sharma A., Shaw S. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis. J Ped Health Care 2009, 48(11):1110-1119. [Epub ahead of print]. DOI:10.1016/j.pedhc.2011.02.008.
19. Marcus R.N., Owen R., Kamen L., et al. Aplacebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. JAm Acad Child Adolesc Psychiatry 2009, 48(11):1110-1119.
20. Owen R., Sikich L., Marcus R.N., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
21. Potenza M.N., Holmes J.P., Kanes S.J., et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. JClin Psychopharmacol 1999, 19(1):37-44.
22. Malone R.P., Delaney M.A., Hyman S.B., et al. Ziprasidone in adolescents with autism: an open-label pilot study. JChild Adolesc Psychopharmacol 2007, 17(6):779-790.
23. Martin A., Koenig K., Scahill L., et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. JChild Adolesc Psychopharmacol 1999, 9(2):99-107.
24. Correll C.U., Kane J.M. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. JChild Adolesc Psychopharmacol 2007, 17(5):647-656.
25. Correll C.U. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. JAm Acad Child Adolesc Psychiatry 2008, 27:9-20.
26. ECDEU assessment manual for psychopharmacology: Publication ABM 76-338 1976, 534-537. US Department of Health, Education, and Welfare, Washington, DC. W. Guy (Ed.).
27. Kaplan G., Newcorn J.H. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am 2011, 58(1):99-120.
28. Handen B.L., Johnson C.R., Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. JAutism Dev Disord 2000, 30:245-255.
29. Quintana H., Birmaher B., Stedge D., et al. Use of methylphenidate in the treatment of children with autistic disorder. JAutism Dev Disord 1995, 25:283-294.
30. Hollander E., Chaplin W., Soorya L., et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010, 35:990-998.
31. Parikh M.S., Kolevzon A., Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. JChild Adolesc Psychopharmacol 2008, 18(2):157-178.
32. Mandell D.S. Psychiatric hospitalization among children with autism spectrum disorders. JAutism Dev Disord 2008, 38(6):1059-1065.
33. Kanner L. Autistic disturbances of affective contact. Nerv Child 1943, 2:217-250.
34. Leekam S.R., Prior M.R., Uljarevic M. Restricted and repetitive behaviors in autism spectrum disorders: a review of research in the last decade. Psychol Bull 2011, 137(4):562-593.
35. McCarthy M., Kolevzon A. Serotonin reuptake inhibitors and other serotonergic medications. Textbook of autism spectrum disorders 2011, 439-455. American Pyschiatric Publishing, Washington, DC. A. Hollander, A. Kolevzon, J.T. Coyle (Eds.).
36. Hollander E., Phillips A., Chaplin W., et al. Aplacebo controlled crossover trial ofliquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005, 30:582-589.
37. SOFIA. Available at: Accessed July 28, 2011. http://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia.
38. King B.H., Hollander E., Sikich L., et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009, 66(6):583-590.
39. Owley T., Walton L., Salt J., et al. An open-label trial of escitalopram in pervasive developmental disorders. JAm Acad Child Adolesc Psychiatry 2005, 44(4):343-348.
40. McDougle C.J., Scahill L., Aman M.G., et al. Risperidone for the core symptom domains of autism: results from the RUPP Autism Network study. Am J Psychiatry 2005, 162:1142-1148.
41. Hollander E., Soorya L., Wasserman S., et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006, 9(2):209-213.
42. McCracken J.T. Disruptive behaviors. Autism spectrum disorders 2010, 159-167. American Psychiatric Publishing, Washington, DC. E. Hollander, A. Kolevzon, J.T. Coyle (Eds.).
43. Murray M.J. Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders. Curr Psychiatry Rep 2010, 12(5):382-388.
44. Gadow K.D., DeVincent C.J., Pomeroy J. ADHD symptom subtypes in children with pervasive developmental disorder. JAutism Dev Disord 2006, 36(2):271-283.
45. APA DSM-5 Development. Available at: Accessed July 28, 2011. http://www.dsm5.org/ProposedRevision/Pages/proposedrevision.aspx%3Frid=383.
46. RUPP Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Arch Gen Psychiatry 2005, 62(11):1266-1274.
47. Paykina N., Greenhill L. Attention deficit hyperactivity disorder. Clinical manual of child and adolescent psychopharmacology 2008, 33-87. American Pyschiatric Publishing, Washington, DC. R.L. Findling (Ed.).
48. Arnold L.E., Aman M.G., Cook A.M., et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. JAm Acad Child Adolesc Psychiatry 2006, 45(10):1196-1205.
49. Jaselskis C.A., Cook E.H., Fletcher K.E., et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. JClin Psychopharmacol 1992, 12(5):322-327.
50. Scahill L., Aman M.G., McDougle C.J., et al. Aprospective open trial of guanfacine in children with pervasive developmental disorders. JChild Adolesc Psychopharmacol 2006, 16(5):589-598.
51. Fatemi S.H., Realmuto G.M., Khan L., et al. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. JAutism Dev Disord 1998, 28(4):303-307.
52. McDougle C.J., Naylor S.T., Cohen D.J., et al. Adouble-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996, 53(11):1001-1008.
53. Richdale A. Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child Neurol 1999, 41:60-66.
54. Cortesi F., Giannotti F., Ivanenko A., et al. Sleep in children with autistic spectrum disorder. Sleep Med 2010, 11(7):659-664.
55. Sánchez-Barceló E.J., Mediavilla M.D., Reiter R.J. Clinical uses of melatonin in pediatrics. Int J Pediatr 2011, 2011:892624.
56. Vriend J.L., Corkum P.V., Moon E.C., et al. Behavioral interventions for sleep problems in children with autism spectrum disorders: current findings and future directions. JPediatr Psychol 2011, 36(9):1017-1029.